Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0002052113-25-002469
Filing Date
2025-07-16
Accepted
2025-07-16 19:02:16
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 5679
2 EXHIBIT 24: POWER OF ATTORNEY PowerOfAttorney.txt EX-24 2796
3 EXHIBIT 99: ITEM 7 Item_7.txt EX-99 645
  Complete submission text file 0002052113-25-002469.txt   11110
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Subject) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-89456 | Film No.: 251128426
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 50 HUDSON YARDS NEW YORK NY 10001
Business Address 50 HUDSON YARDS NEW YORK NY 10001 (212) 810-5800
BlackRock, Inc. (Filed by) CIK: 0002012383 (see all company filings)

EIN.: 991116001 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 6211 Security Brokers, Dealers & Flotation Companies
(CF Office: 02 Finance)